Abstract
Background: Meis1 is a member of three-amino-acid loop extension (TALE) homeodomain transcription factors. Studies in the last decade have shown that Meis1 has crucial roles in cardiac regeneration, stem cell function, and tumorigenesis.
Objective: We have recently demonstrated that knocking out of Meis1 in adult cardiomyocytes resulted in the induction of cardiomyocyte proliferation. This suggests that targeting of Meis1 might be utilized in the manipulation of cardiomyocyte cell cycle post cardiac injuries. In addition, hematopoietic stem cell (HSC) specific deletion of Meis1 leads to in vivo expansion of HSCs pool. Thus, targeting Meis1 may lead to not only cell cycle entry but also ex vivo and in vivo expansion of HSCs. On the other hand, Meis1 transcriptionally regulates the expression of hypoxic tumor markers, namely Hif-1α and Hif-2α. Hif-1α and Hif-2α are involved in the induction of cytoplasmic glycolysis and scavenging of reactive oxygen species (ROS), respectively.
Conclusion: Studies highlight emerging roles of Meis1 towards development of new therapeutic approaches in the treatment of myocardial injuries, bone failure, and cancer.
Keywords: Meis1, cardiac regeneration, stem cell expansion, cancer metabolism, cancer stem cells.
Current Drug Targets
Title:Emerging Roles of Meis1 in Cardiac Regeneration, Stem Cells and Cancer
Volume: 19 Issue: 2
Author(s): Merve Aksoz, Raife Dilek Turan, Esra Albayrak and Fatih Kocabas*
Affiliation:
- Department of Genetics and Bioengineering, Regenerative Biology Research Laboratory, Faculty of Engineering, Yeditepe University, Istanbul 34755,Turkey
Keywords: Meis1, cardiac regeneration, stem cell expansion, cancer metabolism, cancer stem cells.
Abstract: Background: Meis1 is a member of three-amino-acid loop extension (TALE) homeodomain transcription factors. Studies in the last decade have shown that Meis1 has crucial roles in cardiac regeneration, stem cell function, and tumorigenesis.
Objective: We have recently demonstrated that knocking out of Meis1 in adult cardiomyocytes resulted in the induction of cardiomyocyte proliferation. This suggests that targeting of Meis1 might be utilized in the manipulation of cardiomyocyte cell cycle post cardiac injuries. In addition, hematopoietic stem cell (HSC) specific deletion of Meis1 leads to in vivo expansion of HSCs pool. Thus, targeting Meis1 may lead to not only cell cycle entry but also ex vivo and in vivo expansion of HSCs. On the other hand, Meis1 transcriptionally regulates the expression of hypoxic tumor markers, namely Hif-1α and Hif-2α. Hif-1α and Hif-2α are involved in the induction of cytoplasmic glycolysis and scavenging of reactive oxygen species (ROS), respectively.
Conclusion: Studies highlight emerging roles of Meis1 towards development of new therapeutic approaches in the treatment of myocardial injuries, bone failure, and cancer.
Export Options
About this article
Cite this article as:
Aksoz Merve , Turan Dilek Raife , Albayrak Esra and Kocabas Fatih *, Emerging Roles of Meis1 in Cardiac Regeneration, Stem Cells and Cancer, Current Drug Targets 2018; 19(2) . https://dx.doi.org/10.2174/1389450118666170724165514
DOI https://dx.doi.org/10.2174/1389450118666170724165514 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Endothelin Receptor Antagonists: Another Potential Alternative for Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19
Current Drug Targets Microparticles as Biomarkers of Vascular Dysfunction in Metabolic Syndrome and its Individual Components
Current Vascular Pharmacology Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology Effects of Metabolic Approach in Diabetic Patients with Coronary Artery Disease
Current Pharmaceutical Design Application of Current Diagnostic Criteria for Arrhythmogenic Right Ventricular Cardiomyopathy in Every Day Clinical Practice
Current Pharmaceutical Design Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Heme Oxygenase-1 in Cardiovascular Function
Current Pharmaceutical Design Flavonoids as Potential Therapeutic Agents for the Management of Diabetic Neuropathy
Current Pharmaceutical Design Effect of β-Blockers on Perioperative Myocardial Ischemia in Patients Undergoing Noncardiac Surgery
Current Drug Targets Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Current Gene Therapy Innate Immunity and the Heart
Current Pharmaceutical Design Decreased Vascular Repair and Neovascularization with Ageing: Mechanisms and Clinical Relevance with an Emphasis on Hypoxia- Inducible Factor-1
Current Molecular Medicine Treatment of the Cheyne-Stokes Breathing Pattern in Patients with Congestive Heart Failure: An Update
Current Respiratory Medicine Reviews Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets Molecular Mechanisms of Inherited Arrhythmias
Current Genomics Non-glycemic Adverse Effects of Insulin
Current Diabetes Reviews Models and Methods in Cardiac Imaging for Metabolism Studies
Current Pharmaceutical Design Translational Applications of Tissue Engineering in Cardiovascular Medicine
Current Pharmaceutical Design